140 related articles for article (PubMed ID: 8267575)
1. Intermolecular disulfide linkages are not required for transthyretin amyloid fibril formation in vitro.
McCutchen SL; Kelly JW
Biochem Biophys Res Commun; 1993 Dec; 197(2):415-21. PubMed ID: 8267575
[TBL] [Abstract][Full Text] [Related]
2. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
3. Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions.
Zhang Q; Kelly JW
Biochemistry; 2003 Jul; 42(29):8756-61. PubMed ID: 12873136
[TBL] [Abstract][Full Text] [Related]
4. Transthyretin forms amyloid fibrils at physiological pH with ultrasonication.
Misumi Y; Ueda M; Fujimori H; Shinriki S; Meng W; Kim J; Saito S; Obayashi K; Uchino M; Ando Y
Amyloid; 2008 Dec; 15(4):234-9. PubMed ID: 19065294
[TBL] [Abstract][Full Text] [Related]
5. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
Zhang Q; Kelly JW
Biochemistry; 2005 Jun; 44(25):9079-85. PubMed ID: 15966731
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization.
Hurshman AR; White JT; Powers ET; Kelly JW
Biochemistry; 2004 Jun; 43(23):7365-81. PubMed ID: 15182180
[TBL] [Abstract][Full Text] [Related]
7. Cys114-linked dimers of transthyretin are compatible with amyloid formation.
Karlsson A; Olofsson A; Eneqvist T; Sauer-Eriksson AE
Biochemistry; 2005 Oct; 44(39):13063-70. PubMed ID: 16185074
[TBL] [Abstract][Full Text] [Related]
8. Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form.
Lindhagen-Persson M; Vestling M; Reixach N; Olofsson A
Amyloid; 2008 Dec; 15(4):240-5. PubMed ID: 19065295
[TBL] [Abstract][Full Text] [Related]
9. Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry.
Kingsbury JS; Théberge R; Karbassi JA; Lim A; Costello CE; Connors LH
Anal Chem; 2007 Mar; 79(5):1990-8. PubMed ID: 17261023
[TBL] [Abstract][Full Text] [Related]
10. Disulfide-bond formation in the transthyretin mutant Y114C prevents amyloid fibril formation in vivo and in vitro.
Eneqvist T; Olofsson A; Ando Y; Miyakawa T; Katsuragi S; Jass J; Lundgren E; Sauer-Eriksson AE
Biochemistry; 2002 Nov; 41(44):13143-51. PubMed ID: 12403615
[TBL] [Abstract][Full Text] [Related]
11. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils.
Cardoso I; Goldsbury CS; Müller SA; Olivieri V; Wirtz S; Damas AM; Aebi U; Saraiva MJ
J Mol Biol; 2002 Apr; 317(5):683-95. PubMed ID: 11955017
[TBL] [Abstract][Full Text] [Related]
12. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
Lashuel HA; Lai Z; Kelly JW
Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
[TBL] [Abstract][Full Text] [Related]
14. Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin.
Pasquato N; Berni R; Folli C; Alfieri B; Cendron L; Zanotti G
J Mol Biol; 2007 Feb; 366(3):711-9. PubMed ID: 17196219
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization.
Raghu P; Reddy GB; Sivakumar B
Arch Biochem Biophys; 2002 Apr; 400(1):43-7. PubMed ID: 11913969
[TBL] [Abstract][Full Text] [Related]
16. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
[TBL] [Abstract][Full Text] [Related]
17. Effect of nitric oxide in amyloid fibril formation on transthyretin-related amyloidosis.
Saito S; Ando Y; Nakamura M; Ueda M; Kim J; Ishima Y; Akaike T; Otagiri M
Biochemistry; 2005 Aug; 44(33):11122-9. PubMed ID: 16101296
[TBL] [Abstract][Full Text] [Related]
18. Stability and fibril formation properties of human and fish transthyretin, and of the Escherichia coli transthyretin-related protein.
Lundberg E; Olofsson A; Westermark GT; Sauer-Eriksson AE
FEBS J; 2009 Apr; 276(7):1999-2011. PubMed ID: 19250316
[TBL] [Abstract][Full Text] [Related]
19. Contribution of wild-type transthyretin to hereditary peripheral nerve amyloid.
Yazaki M; Liepnieks JJ; Kincaid JC; Benson MD
Muscle Nerve; 2003 Oct; 28(4):438-42. PubMed ID: 14506715
[TBL] [Abstract][Full Text] [Related]
20. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
Lashuel HA; Wurth C; Woo L; Kelly JW
Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
